Stephen F. Mahoney J.D., MBA
Net Worth
Last updated:
What is Stephen F. Mahoney J.D., MBA net worth?
The estimated net worth of Mr. Stephen F. Mahoney J.D., MBA is at least $1,720,523 as of 16 Sep 2021. He has earned $38,603 from insider trading and has received compensation worth at least $1,681,920 in Magenta Therapeutics, Inc..
What is the salary of Stephen F. Mahoney J.D., MBA?
Mr. Stephen F. Mahoney J.D., MBA salary is $420,480 per year as Chief Financial & Operating Officer and Treasurer in Magenta Therapeutics, Inc..
How old is Stephen F. Mahoney J.D., MBA?
Mr. Stephen F. Mahoney J.D., MBA is 54 years old, born in 1971.
What stocks does Stephen F. Mahoney J.D., MBA currently own?
As insider, Mr. Stephen F. Mahoney J.D., MBA owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
Magenta Therapeutics, Inc. (MGTA) | Chief Financial & Operating Officer and Treasurer | 14,264 | $0 | $0 |
What does Magenta Therapeutics, Inc. do?
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes, which is under Phase I/II clinical trial; CD45-antibody drug conjugate that targets HSCs and immune cells, which is in investigational new drug application enabling studies for potential use as a single-agent in autoimmune diseases and hematology-oncology transplants; and MGTA-145 that is in Phase II clinical trial for use in autologous and allogeneic transplants. The company also has a cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. Magenta Therapeutics, Inc. has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Stephen F. Mahoney J.D., MBA insider trading
Magenta Therapeutics, Inc.
Mr. Stephen F. Mahoney J.D., MBA has made only one insider trade in 2021, according to the Form 4 filled with the SEC. He sold 5,736 units of MGTA stock worth $38,603 on 16 Sep 2021.
As of 16 Sep 2021 he still owns at least 14,264 units of MGTA stock.
Magenta Therapeutics key executives
Magenta Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Jason Gardner Ph.D. (54) Co-Founder, Chief Executive Officer, Pres & Director
- Mr. Stephen F. Mahoney J.D., MBA (54) Chief Financial & Operating Officer and Treasurer